Supporting data for "Characterization of Chinese medicine celastrol and celastrol-loaded biodegradable nanoparticles towards the therapy of obesity and non-alcoholic fatty liver disease"

Obesity and non-alcoholic fatty liver disease (NAFLD) are hallmarked by aberrant lipid accumulation, persistent chronic inflammation and hyperactive endoplasmic reticulum (ER) stress. Warburg effect of aerobic glycolysis in hepatic M1 macrophages is a major cause for metabolic dysfunction and inflammatory stress NAFLD. Plant-derived triterpene celastrol markedly inhibited macrophage M1 polarization and adipocyte hypertrophy in obesity. The present study was designed to identify the celastrol-bound proteins which reprogrammed metabolic and inflammatory pathways in M1 macrophages. On the other hand, as a promising anti-obesity drug, plant-derived celastrol is challenged by poor water solubility and low oral bioavailability in clinical applications. The present study was designed to develop a biocompatible albumin-based nanoparticle carrier system for the controlled release of celastrol and targeted delivery in obesity and NAFLD mice.

The results demonstrated that celastrol might alleviate lipid accumulation, inflammation and fibrosis in the liver via covalent modification of PKM2. Meanwhile, the results indicated that albumin-based nanoparticles may be a general biocompatible drug carrier system for the controlled release of hydrophobic compounds (e.g., celastrol) for the treatment of obesity and NAFLD. This dataset contains the data from experimental results.